<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007925</url>
  </required_header>
  <id_info>
    <org_study_id>Disrupt PAD BTK II</org_study_id>
    <nct_id>NCT05007925</nct_id>
  </id_info>
  <brief_title>Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System</brief_title>
  <official_title>Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shockwave Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shockwave Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the continued safety, effectiveness, and optimal clinical use of the Shockwave&#xD;
      Medical Peripheral IVL System for the treatment of calcified, stenotic BTK arteries.&#xD;
&#xD;
      Post-market, prospective , multi-center, single-arm study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 23, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>At procedure</time_frame>
    <description>Procedure Success defined as ≤50% residual stenosis for all treated target lesions without serious angiographic complications (flow-limiting dissection, perforation, distal embolization, or acute vessel closure) as assessed by the angiographic core lab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Limb Events (MALE) + Post-Operative Death (POD)</measure>
    <time_frame>30 days</time_frame>
    <description>Major Adverse Limb Events (MALE) + Post-Operative Death (POD) at 30 days defined as a composite of:&#xD;
all-cause death&#xD;
above-ankle amputation of the index limb&#xD;
major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis) of the index limb involving a BTK artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious angiographic complications</measure>
    <time_frame>At procedure</time_frame>
    <description>Serious angiographic complications (flow-limiting dissection, perforation, distal embolization, or acute vessel closure) as assessed by the angiographic core lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Success</measure>
    <time_frame>At procedure</time_frame>
    <description>Lesion Success defined as final residual stenosis ≤50% in the target lesion without significant angiographic complications as assessed by the angiographic core lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Primary Patency at 6 and 12 months defined as the absence of both total occlusion (100% diameter stenosis by DUS) in all of the target lesions in a flow pathway, as well as a Clinically-Driven Target Lesion Revascularization (CD-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Relevant Target Lesion Failure (CR-TLF)</measure>
    <time_frame>30 days, 6, 12 &amp; 24 months</time_frame>
    <description>Clinically Relevant Target Lesion Failure (CR-TLF) at 30 days, 6, 12 &amp; 24 months defined as a composite of:&#xD;
CD-TLR&#xD;
Ischemia-related major amputation&#xD;
Clinically relevant target lesion occlusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events (MAE)</measure>
    <time_frame>30 days</time_frame>
    <description>Major Adverse Events (MAE) at 30 days defined as a composite of:&#xD;
Need for emergency surgical revascularization of target limb&#xD;
Unplanned target limb major amputation (above the ankle)&#xD;
Symptomatic thrombus or distal emboli that require surgical, mechanical, or pharmacologic means to improve flow, and extend hospitalization&#xD;
Perforations that require an intervention, including bail-out stenting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VascuQoL</measure>
    <time_frame>30 days, 6, 12 &amp; 24 months</time_frame>
    <description>Quality of Life (QoL) assessed by VascuQoL questionnaire at 30 days, 6, 12 &amp; 24 months, reported as change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-brachial index (ABI) or toe-brachial index (TBI)</measure>
    <time_frame>30 days, 6, 12 &amp; 24 months</time_frame>
    <description>Ankle-brachial index (ABI) or toe-brachial index (TBI) at 30 days, 6, 12 &amp; 24 months, reported as change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford Category</measure>
    <time_frame>30 days, 6, 12 &amp; 24 months</time_frame>
    <description>Rutherford Category at 30 days, 6, 12 &amp; 24 months, reported as change from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Single-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intravascular Lithotripsy</intervention_name>
    <description>Localized peripheral intravascular lithotripsy</description>
    <arm_group_label>Single-arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - General Inclusion Criteria&#xD;
&#xD;
          1. Age of subject is ≥ 18.&#xD;
&#xD;
          2. Subject is able and willing to comply with all assessments in the study.&#xD;
&#xD;
          3. Subject or subject's legal representative has been informed of the nature of the&#xD;
             study, agrees to participate, and has signed the approved consent form.&#xD;
&#xD;
          4. Critical limb ischemia (CLI) in the target limb from the distal segment (P3) of the&#xD;
             popliteal artery to the ankle joint prior to the study procedure with Rutherford&#xD;
             Category 4-5; or Rutherford 3 in the target limb from the distal segment (P3) of the&#xD;
             popliteal artery to the ankle joint prior to the study procedure.&#xD;
&#xD;
          5. Estimated life expectancy &gt;1 year.&#xD;
&#xD;
               -  Angiographic Inclusion Criteria&#xD;
&#xD;
          6. Up to 2 below-the-knee target lesion(s) in native vessels in one or both limbs.&#xD;
&#xD;
          7. Target lesion reference vessel diameter (RVD) between 2.0 mm and 4.0 mm by&#xD;
             investigator visual estimate.&#xD;
&#xD;
          8. Target lesion with ≥70% stenosis by investigator visual estimate.&#xD;
&#xD;
          9. Target lesion length is ≤200 mm by investigator visual estimate. Target lesion can be&#xD;
             all or part of the 200 mm treated zone.&#xD;
&#xD;
         10. Distal reconstitution of at least one pedal vessel (&lt;50% stenosis) (desert foot&#xD;
             excluded).&#xD;
&#xD;
         11. Evidence of at least moderate calcification at the target lesion site by&#xD;
             angiography/IVUS OR non-dilatable lesion indicating presence of calcium. Must meet one&#xD;
             of the following:&#xD;
&#xD;
               1. Angiography requires fluoroscopic evidence of calcification on parallel sides of&#xD;
                  the vessel and extending &gt; 50% the length of the lesion.&#xD;
&#xD;
               2. IVUS requires presence of ≥270 degrees of calcium over the course of at least&#xD;
                  10mm.&#xD;
&#xD;
               3. Non-dilatable lesion requires attempted treatment with PTA during the index&#xD;
                  procedure with residual stenosis &gt; 50% and no serious angiographic complications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - General Exclusion Criteria&#xD;
&#xD;
          1. Rutherford Category 0, 1, 2 or 6 (target limb).&#xD;
&#xD;
          2. Osteomyelitis or deep soft tissue infection extending proximal from the metatarsals&#xD;
             that cannot be treated with an individual toe ray amputation or transmetatarsal&#xD;
             amputation (TMA) .&#xD;
&#xD;
          3. History of endovascular or surgical procedure on the target limb within the last 30&#xD;
             days, or planned within 30 days of the index procedure.&#xD;
&#xD;
          4. Subject in whom antiplatelet or anticoagulant therapy is contraindicated.&#xD;
&#xD;
          5. Subject has known allergy to contrast agents or medications used to perform&#xD;
             endovascular intervention that cannot be adequately pre-treated.&#xD;
&#xD;
          6. Subject has known allergy to urethane, nylon, or silicone.&#xD;
&#xD;
          7. Myocardial infarction within 30 days prior to enrollment.&#xD;
&#xD;
          8. History of stroke within 60 days prior to enrollment.&#xD;
&#xD;
          9. Subject has acute or chronic renal disease with eGFR &lt;30 ml/min/1.73 m2 (using CKD-EPI&#xD;
             formula), unless on renal replacement therapy.&#xD;
&#xD;
         10. Subject is pregnant or nursing.&#xD;
&#xD;
         11. Subject is participating in another research study involving an investigational agent&#xD;
             (pharmaceutical, biologic, or medical device) that has not reached the primary&#xD;
             endpoint.&#xD;
&#xD;
         12. Subject has other medical, social or psychological problems that, in the opinion of&#xD;
             the investigator, preclude them from receiving this treatment, and the procedures and&#xD;
             evaluations pre- and post-treatment.&#xD;
&#xD;
         13. Covid-19 diagnosis within 90 days.&#xD;
&#xD;
         14. The planned use of cutting/scoring balloons, re-entry or atherectomy devices in target&#xD;
             lesions during the index procedure.&#xD;
&#xD;
         15. Planned major amputation (of either leg).&#xD;
&#xD;
         16. Acute limb ischemia.&#xD;
&#xD;
         17. Occlusion of all the inframalleolar outflow arteries/vessels (i.e., desert foot).&#xD;
&#xD;
         18. Subject has an anticipated life span of less than one (1) year.&#xD;
&#xD;
         19. Subject already enrolled into this study.&#xD;
&#xD;
               -  Angiographic Exclusion Criteria&#xD;
&#xD;
         20. Failure to treat clinically significant inflow lesions in the ipsilateral iliac,&#xD;
             femoral, or popliteal arteries with ≤30% residual stenosis, and no serious&#xD;
             angiographic complications (e.g., embolism).&#xD;
&#xD;
         21. Failure to successfully treat significant non-target infra-popliteal lesions prior to&#xD;
             treatment of target lesion(s). Successful treatment is defined as obtaining ≤50%&#xD;
             residual stenosis with no serious angiographic complications (e.g., embolism ).&#xD;
&#xD;
         22. Failed PTA in target lesion during index procedure with angiographic evidence of&#xD;
             serious angiographic complications .&#xD;
&#xD;
         23. Target lesion includes in-stent restenosis.&#xD;
&#xD;
         24. Evidence of aneurysm or thrombus in target vessel.&#xD;
&#xD;
         25. No calcium or mild calcium in the target lesion.&#xD;
&#xD;
         26. Target lesion within native or synthetic vessel grafts.&#xD;
&#xD;
         27. Failure to successfully cross the guidewire across the target lesion; successful&#xD;
             crossing defined as tip of the guidewire distal to the target lesion in the absence of&#xD;
             flow limiting dissections or perforations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Sullivan</last_name>
    <phone>(219) 730-9402</phone>
    <email>jsullivan@shockwavemedical.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

